CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 46 enrolled
Drug / intervention
Furosemide +1 moredrug
Likely dose
Furosemide 1 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02469597
NCT02469597Phase 2Completed
CompareCT.gov

Single Dose of Furosemide to Improve Respiratory Distress in Moderate to Severe Bronchiolitis

Northwell Health·interventional·Posted Jun 11, 2015·Updated Aug 12, 2016

In Brief

A Phase 2 clinical trial evaluating Furosemide and Placebo for Bronchiolitis. Completed, enrolled 46 participants across 1 site.

Detailed Summary

The purpose of this study is to assess if administration of an early single dose of a diuretic (furosemide) to children with moderate to severe bronchiolitis can reduce extravascular lung water in an effort to reduce respiratory rate, retractions, intubations, and length of stay.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBronchiolitis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 11, 2015
Enrollment StartOct 1, 2013
Primary CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 11.1 years ago

Interventions

Furosemidedrug

1 mg/kg intravenous or oral (will give oral unless patient has peripheral IV access in place), maximum dose 10mg (1ml), x 1 dose

Placebodrug

0.1ml/kg intravenous or oral (Normal Saline) (will give oral unless patient has peripheral IV access in place), maximum dose 1ml, x 1 dose